Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

This study tests a new drug called FB825 in adults with moderate-to-severe allergic asthma — the kind caused by allergen triggers — to evaluate its safety and effectiveness at controlling asthma symptoms. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with moderate-to-severe allergic asthma for at least 12 months - Your asthma symptoms reverse or react to standard testing (such as a bronchodilator or methacholine challenge) - Your lung function (FEV1) is at or above 40% of the expected value before using an inhaler **You may NOT be eligible if...** - Your asthma is not allergy-triggered - Your asthma has not been confirmed as moderate-to-severe - Your lung function is too impaired - You have other significant lung or immune conditions Talk to your doctor to see if this trial is right for you.